Compare · DCOY vs NVS
DCOY vs NVS
Side-by-side comparison of Decoy Therapeutics Inc. (DCOY) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DCOY and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $287.12B, about 145009.0x DCOY ($2.0M).
- DCOY has been more active in the news (5 items in the past 4 weeks vs 4 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 1 for DCOY).
- Company
- Decoy Therapeutics Inc.
- Novartis AG
- Price
- -
- -
- Market cap
- $2.0M
- $287.12B
- 1M return
- -
- -3.71%
- 1Y return
- -
- +18.91%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 5
- 4
- Recent ratings
- 1
- 25
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest DCOY
- Amendment: SEC Form SCHEDULE 13G/A filed by Decoy Therapeutics Inc.
- SEC Form S-3 filed by Decoy Therapeutics Inc.
- SEC Form 10-Q filed by Decoy Therapeutics Inc.
- Decoy Therapeutics Named “R&D Solution of the Year” in 2026 BioTech Breakthrough Awards
- Decoy Therapeutics Provides Third Quarter 2026 Business Update
- SEC Form EFFECT filed by Decoy Therapeutics Inc.
- SEC Form 424B3 filed by Decoy Therapeutics Inc.
- SEC Form S-1 filed by Decoy Therapeutics Inc.
- Decoy Therapeutics to Present at The Small Cap Showcase
- Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form FWP filed by Novartis AG
- FDA Approval for LAMPRENE issued to NOVARTIS
- Novartis AG downgraded by Deutsche Bank
- SEC Form 6-K filed by Novartis AG
- Big Pharma Setbacks Create a New Wave of Rebound Plays
- Novartis AG upgraded by HSBC Securities
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
- RBC Capital Mkts initiated coverage on Novartis AG